Immunethep receives grant from Gates Foundation
Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 409 entries.
Entries by Thomas Gabrielczyk
Uniqure readies share stock offering
24th October 2017 in News /by Thomas GabrielczykDutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares.
Voluntary health agency jump-starts Selvitas SEL120 programme
9th August 2017 in News /by Thomas GabrielczykThe Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukaemia (AML).
Uniqures new COO to oversee GMP
7th August 2017 in News /by Thomas GabrielczykGene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
Hansas immunomodulatory enzyme does the job
4th August 2017 in News /by Thomas GabrielczykSweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
J&J intensifies vaccine endeavour with Bavarian Nordic
28th July 2017 in News /by Thomas GabrielczykJohnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
GSK cancels 30 preclinical and clinical programmes
27th July 2017 in News /by Thomas GabrielczykUKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) priority areas.
Ablynx adds Sanofi to its list of pharma partners
20th July 2017 in News /by Thomas GabrielczykBelgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth 2.4bn but comes with an upfront payment of just 23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.
Seventure debuts in Japan with microbiome investment
5th July 2017 in News /by Thomas GabrielczykVenture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment vehicle.